VIDEO: Cequa shows dry eye improvements in previously treated patients

ByBrandon D. Ayres, MD

ByEamon N. Dreisbach

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

CHICAGO — In this Healio Video Perspective from the AAO meeting, Brandon D. Ayres, MD, of Wills Eye Hospital discusses a study exploring the impact of Cequa on patients with dry eye disease who were previously treated with Restasis.

The phase 4 study enrolled patients who were not fully satisfied with Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) results who were then switched to Cequa (cyclosporine ophthalmic solution 0.09%, Sun Pharmaceutical).

“Interestingly, within a month, they saw significant improvement in not only corneal staining but also the modified [Symptom Assessment in Dry Eye] score,” Ayres said.

Reference:

Johnston J. Improvement in total corneal staining and visual acuity with cyclosporine ophthalmic solution 0.09% in a phase 4 study of patients with dry eye disease inadequately controlled by cyclosporine ophthalmic emulsion 0.05%. Presented at: European Society of Cataract and Refractive Surgeons meeting; Sept. 6-10, 2024; Barcelona, Spain.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Ayres reports being a consultant and speaker for Sun Pharmaceutical.

OSN New York and OSN New York Retina

Read more

VIDEO: Cequa shows dry eye improvements in previously treated patients

Reference:

Related Content